Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993
Drug Therapy of Migraine
NEJM 329:1476-1483, Welch,K.M.A., 1993
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Acromegaly:Treatment After 100 Years
BMJ 307:1505-1506, Wass,J.A.H., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
An Open-Label Trial of Bromocriptine in Nonfluent Aphasia
Neurol 42:1637-1638, Sabe,L.,et al, 1992
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Acute Respiratory Failure from Dopamine Agonist Withdrawal
Neurol 42:1843-1844, Riley,D.E.,et al, 1992
A Multi-Center, Double-Blind Study on Slow-Release Bromocriptine in the Treatment of Parkinson's Disease
Neurol 41:1598-1602, Mannen,T.,et al, 1991
Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991
The Apomorphine Test in Parkinsonian Syndromes
JNNP 54:870-872, D'Costa,D.F.,et al, 1991
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Bromocriptine-Induced Hypothermia
Neurol 40:383, Pfeiffer,R.F., 1990
Subcutaneous Apomorphine in the Treatment of Parkinson's Disease
JNNP 53:96-101, Frankel,J.P.,et al, 1990
Nasogastric and Intravenous Infusions of (+) -4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's Disease
JNNP 53:102-105, 1990, Coleman,R.J.,et al, 1990
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
Bromocriptine in Parkinson's Disease:A Double-Blind Study Comparing"Low-Slow"and"High-Fast"in de Novo Patients
UK Bromocriptine Res Group, JNNP 52:77-821989., , 1989
Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989
Pergolide and Selegiline for Parkinson's Disease
The Medical Letter, 31:81-841989., , 1989
Agonist Substitution in Advanced Parkinson's Disease
Neurol 39:1121-1122, Goetz,C.G.,et al, 1989
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
PHNO[ (+) -4-Propyl-9-Hydroxynaphthoxazine]:A New and Effective Anti-Parkinson's Disease Agent
Neurol 38:1541-1545, Muenter,M.D.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Pharmacotherapy for Aphasia
Neurol 38:877-879, Albert,M.L.,et al, 1988
A Double-Blind Randomized Crossover Trial of Bromocriptine & Placebo in Restless Legs Syndrome
Ann Neurol 24:455-458, Walters,A.S.,et al, 1988
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
Pleuropulmonary & Retroperitoneal Fibrosis Associated with Bromocriptine Treatment
JNNP 50:1706-1707, Ward,C.D.,et al, 1987
Treatment of Gilles de la Tourette's Syndrome:Experience in a Predominantly Adult Population
Neurol 37:1828-1833, Mesulam,M.M.&Peterson,R.C., 1987
Giant Invasive Prolactinomas
Am J Med 83:995-1002, Murphy,F.Y.,et al, 1987
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Low-Dose Bromocriptine Therapy in Parkinson's Disease:Double-Blind, Placebo-Controlled Study
Neurol 36:291-293, Staal-Schreinemachers,A.L.,et al, 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985
Long-Term Study of Pergolide in Parkinson's Disease
Neurol 35:296-299, Jankovic,J., 1985
Placebo-Controlled Study of Mesulergine in Parkinson's Disease
Neurol 35:161-165, Jankovic,J.,et al, 1985
Hyperthermia after Discontinuance of Levodopa & Bromocriptine Therapy:Impaired Dopamine Receptors a Possible Cause
Neurol 35:258-261, Figa-Talamanca,L.,et al, 1985
Low-Dose Bromocriptine Therapy in Parkinson's Disease
Arch Neurol 42:586-588, Pfeiffer,R.F.,et al, 1985
Mesulergin (CU32-085) in the Treatment of Parkinson's Disease
Ann Neurol 17:334-336, Pfeiffer,R.F.,et al, 1985
Neuroleptic Malignant Syndrome
NEJM 313:163-166, Guze,B.H.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985